PEDIATRIC VACCINES MARKET ANALYSIS

Pediatric Vaccines Market, By Vaccine Type (Pneumococcal Vaccine, DTP Vaccine, Rotavirus Vaccine, MMR Vaccine, Polio Vaccine, Influenza Vaccine, Hepatitis B Vaccine, Meningococcal Vaccine, Hib Vaccine, Varicella Vaccine), By Technology (Live or Attenuated Vaccine, Inactivated or Killed Vaccine, Toxoid Vaccine, Conjugate Vaccine, Subunit Vaccine, Recombinant Vaccine), By Type (Monovalent Vaccine and Multivalent Vaccine), By Distribution Channel (Government and Private), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Mar 2023
Code : CMI1708
Pages :190
Formats :
Excel and PDF
Industry : Biotechnology

Market News

Global Pediatric Vaccines Market: Key Developments

On August 5, 2022, The Republic of the Congo launched a preventive mass vaccination campaign with aim to vaccinate more than 93% of the population against yellow fever. This campaign will target over 4 million people in 11 out of the 12 healthcare departments across the Republic of the Congo The country has set a goal of achieving more than 95% of national vaccine coverage. The campaign is supported by Gavi, a Vaccine Alliance, United Nations Children's Fund (UNICEF), and the World Health Organization (WHO) and partners.

According to an article published by the Lancet Infectious Diseases Journal, a peer-reviewed scientific journal, in October 2021, a clinical study was conducted in Ho Chi Minh City, Vietnam, to determine the immunogenicity of alternative ten-valent pneumococcal conjugate vaccine (PCV 10) schedules in infants of age two months. The results of this study revealed that three-dose primary vaccination series was more efficient in providing protection against pneumococcal bacteria as compared to two-dose primary vaccination series.

For instance, on June 22, 2022, Contra Costa, U.S., announced that it will run vaccination clinics in order to provide safe and effective COVID vaccines to children age 6 months to 4 years old. The U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the Western States Scientific Safety Review Workgroup, authorized pediatric versions of Pfizer's and Moderna's vaccines for above age group. Earlier, only children of age more than 5 years and adults were eligible to receive COVID vaccinations.